Remove 2014 Remove Cannabinoids Remove Clinical Trials Remove Treatment
article thumbnail

Missouri Republican,Michael Davis, proposes adding access to LSD, MDMA, peyote, and psilocybin as treatment options

Cannabis Law Report

Right-to-try aims to allow patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments. Missouri has had its own version of right-to-try since 2014.

article thumbnail

United States Minor Cannabinoids (CBG, CBC, CBN, THCV, CBGA) Markets Report 2021-2028 – ResearchAndMarkets.com

Cannabis Law Report

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cannabis Corporate Virus Spreads Across The Pond … Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach

Cannabis Law Report

Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach.

article thumbnail

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% 2014; 7: 115-124. billion in 2030.

article thumbnail

Best strains and terpenes for pain management

The Cannigma

Over 10% of US adults have suffered from some degree of daily pain for at least three months, so the need for improved treatment is clear. There have been a number of preclinical and clinical trials studying cannabis’ effects on pain. When this system alone can’t manage the pain, outside cannabinoids like THC can help.

Terpenes 111
article thumbnail

Best weed strains for sex

The Cannigma

With this method, you’ll be looking at the most dominant cannabinoids and terpenes in a given cannabis plant, and will choose your cannabis based on their known properties. There are many studies that can speak to these effects, but most of them are pre-clinical, which means they don’t involve human participants. Depression.

Strains 145
article thumbnail

U.S. Funding Focuses on Marijuana’s Harms, Not Benefits

CannaMD

research on marijuana harms – such as cannabis withdrawal, treatments for substance abuse and use/exposure during pregnancy or infancy – received 20 times more funding than research on cannabis therapeutics. While some funds are being used to study cannabis medical treatments, the majority of funding is still used to research harms.

DEA 105